Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 174   

Articles published

PFE 35.00 +0.47 (1.36%)
price chart
Is Pfizer (PFE) on the Retirement Buy List?
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY) recently received some good news from the FDA, which permitted the companies to go to Phase 3 trials for their terminal cancer pain drug, tanezumab.
Morning Buzz: Micron Technology, Inc. (MU), Pfizer Inc. (PFE), Mondelez ...  WallStreet Scope
It's Like Viagra for Pharma Ads: Pfizer's $1.4 Billion Marketing Blitz
Pfizer Inc.'s tab to keep its best-selling drugs on top and turn its newer ones into tomorrow's blockbusters? More than $1 billion.
Pfizer Inc. (PFE)'s Stock May Outperform in 2015-Here's Why
Pfizer Inc. (NYSE:PFE) has seen its earnings and revenue plummet during the last several years as generic drug makers invaded the market with their lower priced alternatives.
Stock to Follow: Pfizer Inc. (NYSE:PFE)  Street Report
Morning Movers to Watch - Pfizer (PFE), AK Steel (AKS), Alcoa (AA), Cisco ...  Techsonian (press release)
Why Pfizer Inc. Isn't Built to Last
In its recent investor presentation, Pfizer's management prepped investors for a major shakeup, stating that they are "establishing the groundwork required to operationalize a potential split of the company". Soon thereafter, Pfizer announced the $17 ...
Top Healthcare Performing Stocks: Pfizer Inc. (NYSE:PFE), Amarin Corporation ...
Pfizer Inc. (NYSE:PFE) [Detail Analytic Report] reported that Diem Nguyen, Regional President, Global Established Pharma will give presentation at the Goldman Sachs Biosimilars Summit on April 2, 2015 at 8:30 a.m.
Pfizer Inc. (PFE) Closes 1.36% Up on the Day for March 30
Pfizer Inc. currently has a total float of 6.13 billion shares and moves 28.25 million a day, on average. The stock opened at $34.60 on March 30 and traded between a low of $34.55 and a high of $35.22.
Pfizer Pushes Through Key Resistance Level
Pfizer Inc. (NYSE: PFE) shares were trading sharply higher by $0.95 (2.8 percent) at $35.20 in Monday's session. The catalyst for the rally may be a price target increase by Jefferies, which bumped its target from $42 to $45.
Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA ...
Hal Mintz's Sabby Capital has initiated a passive stake in Superconductor Technologies, Inc. (NASDAQ:SCON) according to a schedule 13G form filed with the SEC.
Pfizer (PFE) - Analysts' Recent Ratings Changes
Although Pfizer's fourth quarter results were better-than-expected with the company beating on both earnings and revenues despite the presence of generic competition and unfavorable currency movement, the company's guidance for 2015 fell well short of ...
Pfizer, Lilly to resume study testing pain drug
(Reuters) - Pfizer Inc and Eli Lilly and Co will resume late-stage studies of their drug tanezumab for chronic pain after the U.S.
Pfizer, Lilly to Resume Studies of Pain Treatment Tanezumab  Wall Street Journal
Pfizer Inc, Eli Lilly To Recommence Phase 3 Trials For Pain Drug Tanezumab  Bidness ETC